ORIENT-11: Sintilimab plus Pemetrexed plus Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

被引：0
|
作者：
Zhang, L. [1 ]
Yang, Y. [1 ]
Wang, Z. [2 ]
Fang, J. [3 ]
Yu, Q. [4 ]
Han, B. [5 ]
Cang, S. [6 ]
Chen, G. [7 ]
Mei, X. [8 ]
Yang, Z. [9 ]
Ma, R. [10 ]
Bi, M. [11 ]
Ren, X. [12 ]
Zhou, J. [13 ]
Li, B. [14 ]
Xu, W. [15 ]
Ji, Y. [15 ]
Peng, B. [15 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Shandong Prov Canc Hosp, Jinan, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing, Peoples R China
[4] Tumor Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[5] Shanghai Chest Hosp, Shanghai, Peoples R China
[6] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Anhui Prov Hosp, Hefei, Peoples R China
[9] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[10] Liaoning Canc Hosp, Shenyang, Peoples R China
[11] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
[15] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期
关键词：
anti-PD-1; antibody; chemotherapy; nsqNSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ID:1329
引用
收藏
页码：E41 / E41
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Millier, A.
    Clay, E.
    Insinga, R.
    Arunachalam, A.
    Khandelwal, A.
    Bachelot, Levy L.
    Levy, P.
    VALUE IN HEALTH, 2019, 22 : S458 - S458
  • [32] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
  • [33] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China (vol 12, 66, 2022)
    Liu, Huiqin
    Wang, Ying
    He, Qi
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [34] First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
    Shen, Jian
    Du, Yi
    Shao, Rong
    Jiang, Rong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] RATIONALE-304 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo for locally advanced or metastatic non-squamous (NSQ) NSCLC
    Ma, Z.
    Yu, Y.
    Yu, X.
    Li, X.
    Cui, J.
    Wang, D.
    Wang, X.
    Wu, J.
    Huang, D.
    Li, G.
    Zhao, N.
    Liang, L.
    Song, M.
    Lu, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1637
  • [36] Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin plus /- Pembrolizumab in Metastatic Non-Squamous NSCLC
    Miller, J.
    Brown, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1084
  • [37] A Phase II Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed in Elderly Patients with Advanced Non-Squamous NSCLC
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Goto, Koichi
    Yoh, Kiyotaka
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Tanaka, Hiroshi
    Abe, Tetsuya
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S316 - S316
  • [38] Letter Re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
    Zhu, Hao
    Wang, Fa-Lin
    Liu, Jia-Ren
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [39] Health-Related Quality of Life (HRQoL) with Pembrolizumab or Placebo plus Pemetrexed plus Platinum in Patients with Metastatic Non-Squamous NSCLC: Keynote-189
    Hui, R.
    Garassino, M. C.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    Domine, M.
    Hochmair, M. J.
    Powell, S.
    Cheng, S. Y-S
    Bischoff, H. G.
    Peled, N.
    Reck, M.
    Garon, E. B.
    Boyer, M.
    Yang, J.
    Burke, T.
    Pietanza, M. C.
    Gandhi, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 47 - 47
  • [40] Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience
    Bose, Subhadeep
    Khaja, Mujtaba Syed
    Siva, Asha
    Wilson, Paula
    Grist, Helen
    Murukesh, Nishanth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345